Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP).
Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Paola Queirolo, Andrea Antonuzzo(Azienda Ospedaliera Universitaria Pisana), Mario Mandalà(University of Perugia), Michele Maio(University of Siena), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Virginia Ferraresi(Cancer Institute (WIA)), Federica De Galitiis(Istituto Dermopatico dell'Immacolata), Jacopo Pigozzo(Istituto Oncologico Veneto), Francesco Cognetti(Apple (Israel)), Laura Ridolfi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Vito Vanella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Guida(Istituto Tumori Bari), Emilia Cocorocchio(European Institute of Oncology), Giorgio Parmiani(Fondazione IRCCS Istituto Nazionale dei Tumori), Massimo Aglietta(Candiolo Cancer Institute), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Grazia Bernengo(University of Turin), Riccardo Danielli(University of Siena)
Cited by 5
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k